An observational study in Dementia, Motor Neuron Disease and Multiple Sclerosis, sponsored by University of Edinburgh. Recruiting at 1 site in United Kingdom. Open to participants aged 16 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-10.
Sponsored by University of Edinburgh · Observational
Among 178 studies in Dementia with a site in United Kingdom — 40 open to participants now, 58 under way, 12 of them phase 3. Dementia · United Kingdom.
Among the 178 studies in Dementia with a site in United Kingdom, this one is the 31st largest by planned enrollment of the 54 observational ones that give a count, is one of 13 that started in 2024, is one of 54 observational ones, reaches primary completion later than 45 of the 57 other live ones, and was the 141st registered.
2,372 studies on the registry are indexed under Dementia; 574 are open to participants now.
Browse Dementia studies →40 of the 178 studies in Dementia with a site in United Kingdom are open now. Recruiting first, the newest first:
University College, London · Sites in United Kingdom
Ages 55+
Bristol-Myers Squibb · Sites in United Kingdom, United States, Australia and 2 more countries
Ages 55–90
Northumbria Healthcare NHS Foundation Trust · Sites in United Kingdom
Ages 65+
Exciva GmbH · Sites in United Kingdom, United States, Canada and 6 more countries
Ages 55–90
University of Nottingham · Sites in United Kingdom
Ages 18–99 · Healthy volunteers
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 381 Dementia studies recruiting now, 242 (64%) set no upper age limit and 25 (7%) stop at 75 or younger; 16 take children under 18; 163 take healthy volunteers.
This study: 16 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
178 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 34 · Phase 3 40 · Phase 4 3
First in 1999; this study’s year is marked. 13 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 150 is below the median of 256 across 553 observational studies indexed under Dementia.
Median enrollment 196 across the 124 interventional studies, 210 across the 54 observational. Of the 94 that completed or were terminated, 27 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
57 of 178 have an industry lead sponsor. The 10 most frequent:
University of Edinburgh is the lead sponsor of 403 studies on the registry; 64 are open to participants now.
University of Edinburgh has 4 studies filed under Dementia — fewer than ten, so there is no comparison to draw.
9 of the studies in Dementia with a site in United Kingdom that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07693114Anglia Ruskin UniversitySupport in Sound: Music Therapy for People Living With Dementia and Companions in Rural Communities | 2026-11-16 |
| NCT06268886Bristol-Myers SquibbStudy to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease | 2026-12-17 |
| NCT07347431Northumbria Healthcare NHS Foundation TrustLarge Language Model for Understanding and Monitoring Elderly Neurocognition | 2026-12-31 |
| NCT03507257Indiana UniversityLongitudinal Early-onset Alzheimer's Disease Study Protocol | 2027-01-01 |
| NCT06263920Lancashire Teaching Hospitals NHS Foundation TrustNeurofrailty: A Study of Late-onset Epilepsy and Its Associations | 2027-01-12 |
Add all 9 to your calendar (.ics) → With an account.
Among the 178 studies in Dementia with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Many people living with neurodegenerative conditions like dementia, motor neuron disease (MND), multiple sclerosis (MS), and Parkinson's disease (PD), suffer from speech problems. Using common digital technologies such as smartphone apps, the investigators can record and analyse speech in detail to provide new information for people living with these conditions, researchers, and healthcare professionals. This study will investigate the use of these digital speech recordings to help diagnose and monitor these conditions.
To take part, participants will have either a diagnosis of dementia, motor neuron disease, Parkinson's disease or Multiple Sclerosis, OR they will have no diagnosis of a neurological condition. Researchers will compare people with a diagnosis of a Neurological condition to those without.
This project aims to create novel speech-based solutions for: 1) Early detection, 2) Monitoring and 3) Stratification of neurodegenerative disorders including dementia, motor neuron disease (MND), Parkinson's disease (PD), and multiple sclerosis(MS). The investigators will develop and validate proof of concept and early-stage algorithms derived from acoustic data, which will be scaled and tested in deeply-phenotyped population.
2.2 Objectives Primary Objectives
Secondary Objectives
Participants with Neurodegenerative Disorders and their relatives or carers without a diagnosis of a Neurodegenerative disorder.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Primary outcome measures
Area under the curve (AUC) of the receiver operating characteristic (ROC) curve for each of the 4 binary classifiers distinguishing between a disease-positive group and a healthy control group.
Time frame: 24 months
Secondary outcome measure
Sensitivity, specificity, positive and negative predictive values for each of the 4 binary classifiers distinguishing between a disease-positive group and a healthy control group.
Time frame: 24 months
Secondary outcome measure
Mean squared error of 4 regression models making predictions of condition-specific clinical rating scores (ACE-III, ALSFRS-R, EDSS, MDS-UPDRS)
Time frame: 24 months
Plan to share: No
Started Jul 2024 (actual). Primary completion is estimated for Jan 2029, 54 months after the start.
Of 271 non-industry observational studies under Dementia, half reached primary completion within 74 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 202. This study's planned 54 months is below that.
Counting every sponsor, half of 293 studies reached it within 67 months; a quarter within 29 and three quarters within 188.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.